Navigation Links
Methadone and Other Opioids Not Always Equivalent, Conversion Can Be Lethal

As Lower-Cost Methadone Prescribing Increases, Knowledge is Critical

SAN ANTONIO, Feb. 4 /PRNewswire-USNewswire/ -- In a unique and comprehensive literature review of poisoning deaths involving opioids from 1999 -- 2009, the deaths involving methadone were found to be disproportionately high. Methadone represented less than five percent of all opioid prescriptions but is responsible for a third of the deaths. After four years of investigation, the major underlying cause was found to be fundamental misunderstandings about the properties of the medicine -- a "knowledge deficit" -- especially when converting patients from other opioids.

The results of the literature review, root causes of the increase in poisoning deaths during this time period, and suggested solutions to this issue were presented today at the American Academy of Pain Medicine's 26th Annual Meeting.

After a rapid increase of opioid-related deaths was reported in Utah, then president of the Utah Academy of Pain Medicine, Dr. Lynn Webster decided to find out why, and then find a solution. By reviewing state and federal sources as well as PubMed, he was able to assess demographics, prevalence, and other risk factors related to this significant increase in poisoning deaths involving opioids. Webster found that methadone deaths had more to do with misunderstandings about when to prescribe it, how to convert patients to it from other pain medicines, and how to inform patients about its risks.

"Opioids are important tools that pain physicians need in order to have a full range of treatment options for patients who are suffering," said Dr. Webster. "As a scientist and practitioner dedicated to helping patients and the practice of pain medicine, I wanted to understand the increase in opioid-related deaths, and then bring the pain community together to find a solution."

Webster reviewed published data and case reports and found trends in the information that led him to develop theories about the cause of this increase in opioid deaths. The first was the high-proportion of methadone-related deaths in comparison to other opioids. Although it represented about five percent of the opioid prescriptions in this time period, it was mentioned in one-third of the deaths. The research also showed that one-third of the deaths occurred within five days after a dosage change -- also suggesting that unfamiliarity with the medicine could lead to accidental deaths.

Webster then brought this information to a consensus conference sponsored by the LifeSource Foundation where an esteemed panel of colleagues representing the best in research, practice, epidemiology, and public health helped him determine root causes of the problem. After reviewing and discussing the data, the panel identified the following as probable causes underlying the spike: physician error due to knowledge deficits, patient non-adherence to medication regimen, unanticipated medical and psychiatric co-morbidities (including substance abuse), and payer policies that mandate methadone as a first-line coverage.

"Not all pain medicines -- even within a class -- and not all patients -- are created equally," said Dr. Webster. "Methadone is a safe and effective opioid with pharmacokinetics and pharmacodynamics unlike other opioids, so knowledge about it and how it may affect a specific patient is paramount to a positive clinical outcome. Education about pain medicine is the best safeguard against the unintended deaths and side effects we've seen with methadone in the last decade."

According to Webster, simple conversion from one opioid twice a day to another twice a day is not safe. Patient pharmacogenetics (a patient's unique response to medicine based on his or her genetics), especially when converting between opioids, along with the properties of the medicine, must be taken under advisement to determine appropriate therapy. In addition, he advises that switching a patient to methadone must be done slowly and over time: start with a low dose, and titrate from there in increments that make sense for the patient and the pain condition.    

Additionally, Webster and the panel agreed that to solve the main underlying problem, which they define as a "knowledge deficit," the U.S. Food and Drug Administration, pharmaceutical manufacturers, and scientific experts should use the last decade's worth of data on methadone, as well as his review of the increase from 2001 -- 2005, to guide and determine Risk Evaluation and Mitigations Strategies (REMS) now under consideration.

Dr. Webster and his colleagues are currently involved in an upcoming targeted education program called PainSAFE to help educate physicians and patients about safe opioid prescribing. Information about this can be found online at

About AAPMedicine

For more than 25 years, the American Academy of Pain Medicine (AAPM) has been the medical specialty society representing more than 2,200 physicians practicing in the field of comprehensive pain medicine. The Academy is involved in education, training, advocacy and research in the specialty of pain medicine. Information is available on the practice of pain medicine at

SOURCE American Academy of Pain Medicine



SOURCE American Academy of Pain Medicine
Copyright©2010 PR Newswire.
All rights reserved

Related medicine news :

1. Bioniche Pharma Acquires Duraclon(R) (clonidine hydrochloride injection) and Methadone Hydrochloride Injection USP
2. A New Service for Health Care Providers Who Prescribe Methadone to Treat Chronic Pain or Opioid Addiction
3. Researchers identify potential patient safety risks among methadone maintenance treatment patients
4. New information points to safer methadone use for treatment of pain and addiction
5. Suboxone Fast Passing Methadone As Preferred Method Of Treatment For Opiate Detox
6. Methadone Kills Resistant Leukemia Cells
7. Methadone and systematic follow-up: the best solution for managing chronic pain
8. American Red Cross and Other U.S. Blood Centers Send Blood to Haiti
9. Spanish-Speaking Mothers Less Likely to Turn on TV
10. No Surprise to David Perecman And Other Personal Injury Attorneys, Vehicles Lead All Causes of Injury at New York Hospital
11. DR Vitamins, LLC Introduces Vision Clarity Carnosine Eye Drops to Treat Cataracts, Glaucoma, Dry Eye, or Other Eye Ailments
Post Your Comments:
(Date:11/27/2015)... ... November 27, 2015 , ... ... convenient way to dispense prescription medications at home, so he invented the patent-pending ... monitor and dispense prescription medications. In doing so, it could help to prevent ...
(Date:11/27/2015)... ... 2015 , ... MPWH, the No.1 Herpes-only dating community in the world, revealed that over 50% ... More than 3.7 billion people under the age of 50 – or 67% of the ... first global estimates of HSV-1 infection . , "The data shocks us highly!" said ...
(Date:11/27/2015)... ... November 27, 2015 , ... Keeping in mind challenges ... health and wellness consultation, has collaborated with a leading web-based marketplace for extra-curricular ... experienced by parents and bring advice from parenting experts within their reach. As ...
(Date:11/27/2015)... ... November 27, 2015 , ... Indosoft ... announces the incorporation of Asterisk 11 LTS (Long Term Support) into its Q-Suite ... LTS brings Q-Suite 5.10 up-to-date with a version of Asterisk that will receive ...
(Date:11/26/2015)... ... 2015 , ... The Catalent Applied Drug Delivery Institute today ... dose form selection in early phase drug development. The first of these is ... together the UK’s emerging life sciences companies, corporate partners, and investors, at Milton ...
Breaking Medicine News(10 mins):
(Date:11/26/2015)... , November 26, 2015 ... "Self Administration of High Viscosity Drugs" ... ) has announced the addition of the ... to their offering. --> Research and ... of the "Self Administration of High Viscosity ...
(Date:11/26/2015)... , November 26, 2015 /PRNewswire/ ... announced the addition of the  "2016 ... the European Cell Surface Marker Testing ... Opportunities"  report to their offering.  ... the addition of the  "2016 Future ...
(Date:11/25/2015)... 25, 2015  Amgen (NASDAQ: AMGN ) today ... with the United States (U.S.) ... biosimilar candidate to Humira ® (adalimumab). Amgen believes ... to the FDA and represents Amgen,s first BLA submission ... Harper , M.D., executive vice president of Research and ...
Breaking Medicine Technology: